

Via OTC News & Disclosure Service

April 29, 2024

OTC Markets Group, Inc. – Issuer Services

300 Vesey Street, 12th Floor

New York, NY 10282

Tel: (212) 896-4400

Fax: (212) 868-3848

Re: Adequacy of Current Public Information

Dear Sir or Madam:

I, the undersigned, am an attorney licensed to practice law in the state of California and before the courts of the United States. I am permitted to practice before the Securities and Exchange Commission (“SEC”) and have never been prohibited from practice thereunder. I am United States resident and citizen with a law practice in San Francisco, California. This legal opinion is limited to matters of Federal Securities Law.

I represent that neither myself, nor my firm, is not now, any time prior to, including the past five years, been under investigation for any violation(s) of federal or state securities laws, by agencies such as SEC, FINRA, CTFC or state securities regulators; nor suspended nor barred from practice in any jurisdiction; nor charged in any criminal or civil action. Neither my firm, nor am I the undersigned, directly or indirectly, a shareholder, beneficial interest, or creditor of, the Issuer, and has no agreement to receive in the future, shares of the issuer’s stock, in payment for services, or otherwise.

I have been retained by Branded Legacy, Inc. (“BLEG” or the “Company”) for the purpose of providing advice as to matters of federal securities law and to render a legal opinion on the adequacy of current information available to the public in relation to the filing of an “Information Statement and Disclosure” pursuant to Rule 15c2-11(a) (5) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”), and Rule 144(c)(2) of the Securities Act of 1933 as amended, (the “Securities Act”).

The Company is incorporated under the laws of the state of Utah. The Company filed with the Utah secretary of state on or about July 3, 2023 to change its name to Royal Enterprises,

Inc. A name and symbol change application has been submitted to FINRA OTC corporate actions and is pending approval.

1. Facts & Assumptions

In rendering this opinion, I have reviewed various corporate records and other documentation necessary and proper for an opinion in conjunction with the filing of the Company's Information & Disclosure Statement for the period ending December 31, 2023 and the Quarterly Information & Disclosure Statement for the periods ending March 31, 2023, June 30, 2023 and September 30, 2022.

Additionally, I have made further inquiry and investigation into the laws, regulations, and commentary available for such filings. With respect to corporate documentation examined, I have presumed the genuineness of all signatures thereon; the authenticity of all documents provided as originals; conformity of all copies to the original documents; and the authenticity of all original documents submitted as copies.

I have also relied upon information available on the Internet, from records with the SEC, FINRA, the OTC Markets Group, Inc. ("OTC"), and from officers of the Company in addition to other sources deemed reliable, such as records on file with the Utah secretary of state. Nothing came to my attention during the course of my investigation that led me to conclude that any such documents were not genuine or authentic or that the facts contained therein were not true.

2. Inquiry & Investigation

I have reviewed the Annual Report and the Quarterly Reports for the periods ending December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023. Each report including amendments thereto as well as several supplemental information disclosures have been posted via OTC News and Disclosure Service. The Annual Report (Amended) was posted on April 29, 2023. The Quarterly Reports were posted on November 20, 2023 (September 30, 2023, Amended), September 1, 2023 (June 30, 2023 amended) and May 15, 2023 (March 31, 2023).

The Quarterly Report, although un-audited, was prepared by David Oswald the Company's CEO and prior to him Brandon Spikes (the March 31, 2023 report). Mr. Oswald although not an accountant, has a business degree and extensive experience working on an executive level for public companies and preparing their financial reports. The Annual Report was independently reviewed by Chang Park, a CPA of San Diego, California. Mr. Park, a licensed CPA, has extensive professional experience bookkeeping for public companies and preparing financial statements.

The Company's transfer agent is Securities Transfer Corporation. I have confirmed via electronic mail that this transfer agent is registered with the SEC and that the number of issued

and outstanding shares reflected in the Annual and Quarterly Reports is accurate. Information regarding the accuracy of the shareholder's list and the issued and outstanding shares of the Company can be confirmed with Securities Transfer Corporation Securities Transfer Corporation 2901 N. Dallas Parkway, Suite 380 Plano, Texas 75093, Telephone (469) 633-0101 or email at info@stctransfer.com.

Additionally, I have met (*via Telephone Video Conference*) with the officers and directors David Oswald, Steven Augustine, Andrew Seelund, and Phillip White, to discuss the Annual and Quarterly Reports, the information contained therein, and specifically its adequacy for these purposes.

An interested investor could readily find current information available regarding the Company by which s/he could objectively make a determination pertaining to the corporate financial status and relevant financial information thereby enabling such investor to make an informed and intelligent decision regarding the stock of the company by searching for the Company on the OTC Markets Group, Inc. website at: <https://www.otcmarkets.com/stock/BLEG/disclosure>.

Among the officers and directors of the Company, only David Oswald holds preferred or common shares. He holds three million eight hundred thousand (3,800,000) of the preferred Series E shares. There is no evidence of any investigation or enforcement action of Oswald by state or federal securities regulators.


3. Legal Conclusions

The legal opinion as expressed in this letter is that the Annual Report and Quarterly Report filings for the periods ending, December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023 as filed in their amended form via the OTC Markets Group News and Disclosure Service on April 29, 2023 (December 31, 2023), on November 20, 2023 (September 30, 2023, Amended), September 1, 2023 (June 30, 2023 amended) and May 15, 2023 (March 31, 2023, together constitutes: (1) adequate information about the Company which is available to the public regarding the shares of common stock and is available within the meaning of Rule 144(c)(2) of the Securities Act of 1933; which (2) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the shares of common stock of the Corporation under Rule 15c2-11 of the Exchange Act of 1934; that (3) complies with the OTC Markets, Group Inc. Alternative Reporting Guidelines as they pertain to providing adequate and current information about the Company; and (4) the statement has been posted in the OTC Markets Group, Inc. News and Disclosure Service. OTC Markets Group, Inc. is entitled to rely on this opinion in determining whether the Company has made adequate current information available to the public pursuant to Rule 144(c)(2) of the Securities and Exchange Acts, and may publish this opinion on its website, www.otcmarkets.com, for such limited purposes.

Additionally, (5) the Company is not now “shell company” as such term is defined at Rule 405 of the Securities Act, and 12b-2 of the Exchange Act as it has several operation subsidiaries as further detailed reports and disclosures referenced herein. Although the Company may have previously been a shell company, the Company has changed ownership and business models several times and it is the policy of the SEC not to render transitional companies as shell companies merely because of period of time between the transition between businesses. Because the Company has never been subject to the periodic reporting requirements of the Securities Exchange Act of 1934 or an independent audit, a conclusive determination is impossible.

The statements and opinions set forth herein reflect observations and results of inquiries up to the date hereof, and shall remain valid for as long as the documents, instruments, records and other information I have reviewed and examined remain unchanged, and the assumptions relied upon continue to be valid. This opinion is intended solely for the use and application of OTC Markets Group, Inc. as it deems appropriate for use and publication on its website.

Kind Regards,

A handwritten signature in black ink, appearing to read 'John E. Dolkart, Jr.', with a stylized, cursive script.

John E. Dolkart, Jr., Esq.